Prospera Financial Services Inc reduced its position in shares of Pfizer, Inc. (NYSE:PFE) by 18.3% during the second quarter, Holdings Channel reports. The firm owned 36,799 shares of the biopharmaceutical company’s stock after selling 8,231 shares during the period. Prospera Financial Services Inc’s holdings in Pfizer were worth $1,227,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Asset Planning Services Ltd. increased its stake in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 137 shares during the period. D. Scott Neal Inc. increased its stake in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares during the period. Orrstown Financial Services Inc. increased its stake in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 612 shares during the period. Franklin Parlapiano Turner & Welch LLC purchased a new stake in shares of Pfizer during the first quarter worth $121,000. Finally, Cable Hill Partners LLC increased its stake in shares of Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 265 shares during the period. Institutional investors and hedge funds own 69.94% of the company’s stock.

Shares of Pfizer, Inc. (PFE) traded up 0.015% on Wednesday, reaching $33.385. The company’s stock had a trading volume of 4,531,391 shares. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $35.38. The stock has a 50-day moving average of $33.36 and a 200 day moving average of $33.37. The stock has a market capitalization of $199.24 billion, a price-to-earnings ratio of 24.422 and a beta of 1.00.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The firm had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same period last year, the firm posted $0.64 EPS. The business’s revenue was down 1.9% on a year-over-year basis. On average, analysts expect that Pfizer, Inc. will post $2.56 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be issued a dividend of $0.32 per share. The ex-dividend date is Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a yield of 3.83%. Pfizer’s dividend payout ratio is 94.12%.

COPYRIGHT VIOLATION WARNING: “Pfizer, Inc. (PFE) Shares Sold by Prospera Financial Services Inc” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/pfizer-inc-pfe-shares-sold-by-prospera-financial-services-inc/1496141.html.

A number of brokerages have recently weighed in on PFE. Cowen and Company set a $43.00 price target on Pfizer and gave the company a “buy” rating in a report on Monday. Berenberg Bank reiterated a “hold” rating and issued a $36.00 price target (down from $39.00) on shares of Pfizer in a report on Tuesday. BidaskClub upgraded Pfizer from a “strong sell” rating to a “sell” rating in a report on Saturday, August 5th. UBS AG reiterated a “buy” rating and issued a $38.00 price target on shares of Pfizer in a report on Monday, July 31st. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $35.00 price target (up from $34.00) on shares of Pfizer in a report on Friday, July 14th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $37.61.

In other news, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of Pfizer stock in a transaction on Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the sale, the insider now directly owns 151,474 shares of the company’s stock, valued at $5,074,379. The disclosure for this sale can be found here. Company insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.